30.49
Vera Therapeutics Inc stock is traded at $30.49, with a volume of 788.92K.
It is up +1.33% in the last 24 hours and up +28.27% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$30.09
Open:
$30.42
24h Volume:
788.92K
Relative Volume:
0.54
Market Cap:
$1.95B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-13.80
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
-1.45%
1M Performance:
+28.27%
6M Performance:
+35.93%
1Y Performance:
-28.63%
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VERA
Vera Therapeutics Inc
|
30.49 | 1.92B | 0 | -107.85M | -106.82M | -2.21 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
May-05-25 | Resumed | H.C. Wainwright | Buy |
Feb-04-25 | Initiated | Wolfe Research | Outperform |
Jan-28-25 | Initiated | Goldman | Buy |
Nov-21-24 | Initiated | Wells Fargo | Overweight |
Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
Jan-25-24 | Initiated | Oppenheimer | Outperform |
Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
Dec-18-23 | Initiated | Raymond James | Outperform |
Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
Aug-16-23 | Initiated | Guggenheim | Buy |
Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
Jul-12-22 | Initiated | JP Morgan | Overweight |
May-02-22 | Initiated | H.C. Wainwright | Buy |
Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Can Vera Therapeutics Inc. hit a new high this monthBond Market & Consistent Profit Trade Alerts - newser.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
Ranking Vera Therapeutics Inc. among high performing stocks via toolsTrade Entry Summary & Weekly Watchlist of Top Performers - newser.com
Is Vera Therapeutics Inc. stock overvalued by current metricsJuly 2025 Levels & Reliable Breakout Forecasts - newser.com
Vera Therapeutics Inc. stock trend forecastCPI Data & High Return Stock Watch Alerts - newser.com
Is Vera Therapeutics Inc a good long term investmentBear Market Strategies & Follow Top Performers in the Community - earlytimes.in
Why Vera Therapeutics Inc. stock could rally in 2025Portfolio Return Report & Accurate Buy Signal Notifications - newser.com
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Trend analysis for Vera Therapeutics Inc. this weekTrade Risk Report & Community Consensus Stock Picks - newser.com
Detecting support and resistance levels for Vera Therapeutics Inc.2025 Dividend Review & Fast Entry Momentum Alerts - newser.com
Vera Therapeutics' (VERA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Polycythemia Vera Pipeline 2025: FDA Updates, Therapy - openPR.com
What indicators show strength in Vera Therapeutics Inc.Portfolio Gains Summary & Technical Pattern Alert System - newser.com
Using RSI to spot recovery in Vera Therapeutics Inc.2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Heatmap analysis for Vera Therapeutics Inc. and competitorsBear Alert & AI Powered Buy and Sell Recommendations - newser.com
Will Vera Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - newser.com
Risk vs reward if holding onto Vera Therapeutics Inc.2025 Top Gainers & High Accuracy Swing Trade Signals - newser.com
J. Safra Sarasin Holding AG Takes Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Evaluating Vera Therapeutics Inc. with trendline analysisJuly 2025 Outlook & AI Powered Trade Plan Recommendations - newser.com
Developing predictive dashboards with Vera Therapeutics Inc. dataJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
What drives Vera Therapeutics Inc stock priceLong-Term Growth Stocks & These Stocks Are Just Getting Started - earlytimes.in
Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $75 - 富途牛牛
Vera Therapeutics, Inc. $VERA Shares Purchased by Platinum Investment Management Ltd. - MarketBeat
13,567 Shares in Vera Therapeutics, Inc. $VERA Acquired by GC Wealth Management RIA LLC - MarketBeat
Fifth Third Bancorp Buys New Stake in Vera Therapeutics, Inc. $VERA - Defense World
10,406 Shares in Vera Therapeutics, Inc. $VERA Purchased by Perigon Wealth Management LLC - MarketBeat
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating - 富途牛牛
What analysts say about Vera Therapeutics Inc stockDividend Reinvestment Plans & Low Risk Investment Tips - earlytimes.in
Vera Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Small Entry Investment Ideas - Early Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Shares Up 5.3%Time to Buy? - MarketBeat
Vera Therapeutics (VERA): Assessing Valuation After New KDIGO Guidelines Shape the IgA Nephropathy Market - Sahm
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ENRIGHT PATRICK G | Director |
Jun 24 '25 |
Buy |
22.35 |
40,607 |
907,635 |
3,596,593 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 21 '25 |
Sale |
27.89 |
10,613 |
296,032 |
213,740 |
Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):